Metformin cost effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Metformin Cost-Effectiveness in Diabetes Prevention and Treatment
Cost-Effectiveness of Metformin for Prediabetes and Type 2 Diabetes Prevention
Multiple studies have found that metformin is cost-effective for preventing type 2 diabetes in people with prediabetes when compared to placebo or no intervention. Most analyses report incremental cost-effectiveness ratios (ICERs) for metformin that are below commonly accepted willingness-to-pay thresholds, indicating good value for money spent on metformin in this context Thuy2024Gebregergish2020Herman2012. In some cases, metformin was even found to be cost-saving compared to placebo Thuy2024Herman2012.
Metformin Versus Lifestyle Interventions: Comparative Cost-Effectiveness
When comparing metformin to intensive lifestyle changes (ILC), the evidence is mixed. Several reviews and economic analyses show that while both metformin and lifestyle interventions are cost-effective compared to placebo, lifestyle interventions are often more cost-effective or even dominant (providing better health outcomes at lower or similar costs) compared to metformin Alolayan2025Rittenhouse2023Gebregergish2020+1 MORE. Some studies suggest that metformin may be cost-saving in the short- to medium-term, but over the long term, lifestyle interventions may be less expensive when considering direct medical costs . However, when indirect non-medical costs are included, metformin can sometimes be less expensive than lifestyle interventions .
Real-World Evidence and Broader Populations
Real-world data support the high cost-effectiveness of metformin, especially given its low price and established safety profile. This is particularly important in healthcare systems with limited resources, where the affordability of metformin makes it a practical option for large-scale diabetes prevention and management . Additionally, metformin remains a cost-effective choice across different patient populations and healthcare settings .
Cost-Effectiveness in Special Populations: Gestational Diabetes
In the treatment of gestational diabetes mellitus (GDM), metformin has been shown to be more cost-effective than insulin, resulting in lower costs and better quality-adjusted life years (QALYs) . This finding supports the use of metformin as a first-line treatment option for GDM from a cost-effectiveness perspective.
International and Health System Perspectives
Most cost-effectiveness studies of metformin have been conducted in high-income countries, and their findings may not be directly applicable to low- and middle-income countries due to differences in healthcare costs and resource availability . Nevertheless, the general trend indicates that metformin is a cost-effective intervention for diabetes prevention and management in settings where it is affordable and accessible Thuy2024Gebregergish2020Herman2012+1 MORE.
Conclusion
Overall, metformin is consistently found to be cost-effective for the prevention and management of type 2 diabetes, especially when compared to placebo or no intervention. While lifestyle interventions may offer greater cost-effectiveness in some analyses, metformin remains a valuable and affordable option, particularly in resource-limited settings and for specific populations such as those with gestational diabetes. The choice between metformin and lifestyle interventions should consider local healthcare costs, patient preferences, and system resources.
Sources and full results
Most relevant research papers on this topic